Department of Radiation Oncology at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Department of Radiation Oncology, University of California, Los Angeles, California.
Int J Radiat Oncol Biol Phys. 2024 Jan 1;118(1):124-136. doi: 10.1016/j.ijrobp.2023.08.011. Epub 2023 Aug 12.
Radiation therapy (RT) associates with long-term cardiotoxicity. In preclinical models, RT exposure induces early cardiotoxic arrhythmias including atrial fibrillation (AF). Yet, whether this occurs in patients is unknown.
Leveraging a large cohort of consecutive patients with esophageal cancer treated with thoracic RT from 2007 to 2019, we assessed incidence and outcomes of incident AF. Secondary outcomes included major adverse cardiovascular events (MACE), defined as AF, heart failure, ventricular arrhythmias, and sudden death, by cardiac RT dose. We also assessed the relationship between AF development and progression-free and overall survival. Observed incident AF rates were compared with Framingham predicted rates, and absolute excess risks were estimated. Multivariate regression was used to define the relationship between clinical and RT measures, and outcomes. Differences in outcomes, by AF status, were also evaluated via 30-day landmark analysis. Furthermore, we assessed the effect of cardiac substructure RT dose (eg, left atrium, LA) on the risk of post RT-related outcomes.
Overall, from 238 RT treated patients with esophageal cancer, 21.4% developed incident AF, and 33% developed MACE with the majority (84%) of events occurring ≤2 years of RT initiation (median time to AF, 4.1 months). Cumulative incidence of AF and MACE at 1 year was 19.5%, and 25.7%, respectively; translating into an observed incident AF rate of 824 per 10,000 person-years, compared with the Framingham predicted rate of 92 (relative risk, 8.96; P < .001, absolute excess risk 732). Increasing LA dose strongly associated with incident AF (P = .001); and those with AF saw worse disease progression (hazard ratio, 1.54; P = .03). In multivariate models, outside of traditional cancer-related factors, increasing RT dose to the LA remained associated with worse overall survival.
Among patients with esophageal cancer, radiation therapy increases AF risk, and associates with worse long-term outcomes.
放射治疗(RT)与长期心脏毒性相关。在临床前模型中,RT 暴露会导致早期心脏毒性心律失常,包括心房颤动(AF)。然而,这种情况是否发生在患者身上尚不清楚。
利用 2007 年至 2019 年期间连续接受胸部 RT 治疗的食管癌患者的大型队列,我们评估了新发 AF 的发生率和结局。次要结局包括主要不良心血管事件(MACE),定义为 AF、心力衰竭、室性心律失常和心脏 RT 剂量相关的猝死。我们还评估了 AF 发展与无进展和总生存之间的关系。观察到的新发 AF 发生率与弗雷明汉预测率进行比较,并估计绝对超额风险。多变量回归用于定义临床和 RT 测量与结局之间的关系。还通过 30 天的标志性分析评估了 AF 状态对结局的影响。此外,我们评估了心脏亚结构 RT 剂量(如左心房,LA)对 RT 相关结局风险的影响。
总体而言,在 238 例接受食管癌 RT 治疗的患者中,21.4%发生新发 AF,33%发生 MACE,其中大多数(84%)事件发生在 RT 开始后≤2 年(中位 AF 时间,4.1 个月)。AF 和 MACE 的 1 年累积发生率分别为 19.5%和 25.7%;换算成 10000 人年的观察性新发 AF 率为 824 例,而弗雷明汉预测率为 92 例(相对风险,8.96;P<0.001,绝对超额风险 732)。LA 剂量的增加与新发 AF 强烈相关(P=0.001);并且发生 AF 的患者疾病进展更差(风险比,1.54;P=0.03)。在多变量模型中,除了传统的癌症相关因素外,LA 的 RT 剂量增加与总生存更差相关。
在食管癌患者中,放射治疗会增加 AF 的风险,并与更差的长期结局相关。